Ampyra Approval History

  • FDA approved: Yes (First approved January 22nd, 2010)
  • Brand name: Ampyra
  • Generic name: dalfampridine
  • Previous name: Fampridine-SR
  • Company: Acorda Therapeutics, Inc.
  • Treatment for: Multiple Sclerosis

Ampyra (dalfampridine) is an oral potassium channel blocker indicated to improve walking ability in people with multiple sclerosis.

FDA Approval History for Ampyra

DateArticle
Jan 22, 2010Approval FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis
Oct 22, 2009Acorda Therapeutics Announces Extension of Fampridine-SR PDUFA Goal Date to January 22, 2010
Oct 14, 2009Acorda Therapeutics Announces Positive Vote by FDA Advisory Committee for Fampridine-SR
Aug 25, 2009Acorda Therapeutics Reports Date of FDA Advisory Committee Review of Fampridine-SR for Improvement of Walking Ability in People with MS
May  6, 2009Acorda Therapeutics Announces FDA Acceptance of Fampridine-SR New Drug Application for Filing
Apr 23, 2009Acorda Therapeutics Resubmits New Drug Application for Fampridine-SR for Improvement of Walking Ability in People with Multiple Sclerosis
Mar 31, 2009Acorda Therapeutics Receives Refuse to File Letter from FDA on Fampridine-SR NDA
Feb  2, 2009Acorda Therapeutics Submits NDA for Fampridine-SR for Improvement of Walking Ability in People with Multiple Sclerosis

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide
(web1)